
    
      This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated
      with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy
      (NACT) between 2011 and 2016.

      The primary end points are overall survival (OS) and progression free survival (PFS) with
      Kaplan Meier.

      This study was approved by Ethical Committee in Dharmais National Cancer Hospital.
    
  